A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
收藏DataCite Commons2025-05-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00000158/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This study was designed to determine if the investigational drug is effective and safe in individuals with COPD (chronic pulmonary disease)
提供机构：
Vivli
创建时间：
2018-10-27
